

Chronic obstructive pulmonary disease (COPD) Committee meeting

Date: 04/12/2017

Location: Manchester

Minutes: Draft

Committee members present:	
Andrew Molyneux (Chair)	Present for items 1–6
Katy Beckford	Present for items 2–6
Lauren Hogg	Present for items 1–6
Nick Hopkinson	Present for items 1–6
Sarah MacFadyen	Present for items 1–6
Karen O’Hara	Present for items 1–6
Tony Perkins	Present for items 1–6
Luisa Pettigrew	Present for items 1–6
Louise Restrick	Present for items 1–6
Karen Sennett	Present for items 1–6

In attendance:	
Rupert Franklin Guideline Commissioning Manager	Not required
Marie Harrisingh Technical Analyst	Present for items 1–6
Les Hayes Business Analyst	Not required
Ben Johnson Senior Technical Analyst (HE)	Present for items 1–6
Anneka Patel Project Manager	Present for items 1–6
Joanne Perkin Senior Digital Editor	Not required
Joshua Pink Technical Adviser	Present for items 1–6
Gabriel Rogers Technical Adviser (HE)	Present for items 1–6
Sue Spiers Associate Director	Apologies

Committee minutes – COPD meeting 6

Observing:

Anita Sangha	Assistant Technical Analyst	NICE
--------------	-----------------------------	------

Apologies:

Ravijot Saggu	Committee member
Christopher Warburton	Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the sixth meeting on chronic obstructive pulmonary disease (COPD).

The Chair informed the committee of apologies as listed above.

The Chair asked everyone to verbally declare any new interests arising since the last meeting. The following new declarations were made:

Committee member	Declaration	Classification	Chairs action
Katy Beckford	Ran a study group for Primary care for Respiratory which was funded by various pharma companies, who collectively paid for the room in the hotel.	Non-specific, non-personal, financial	Declare and participate.
Tony Perkins	Change in job title from January 2018 to Lead Respiratory pharmacist, a specific role supporting NEW Devon CCGs respiratory medicines optimisation work streams. Part of the role will involve meeting with representatives of pharma industry, and could involve managing contracts surrounding "partnership working"	Non-specific, personal, non-financial	Declare and participate

Committee minutes – COPD meeting 6

	<p>with drug industry. Not expected any payment or honorariums from pharma industry to be received personally nor would it fund my employment/ post.</p>		
<p>The Chair and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>			
<p>2. Recap of last meeting</p>			
<p>The committee discussed and clarified some points raised at the previous meeting.</p>			
<p>3. Review question - which is the most clinically and cost-effective long-acting anticholinergic for managing stable COPD, and which subgroups of people should receive treatment with it?</p>			
<p>Ravijyot Saggu, Committee member, had provided a summary for the effectiveness of long acting anti-muscarinic agents (LAMA), which was sent out to committee members previously as background information.</p> <p>Marie Harrisingh (MH), technical analyst, presented the available clinical evidence for this review question for the committee’s consideration. MH explained the next steps in the analysis to allow the review question to be answered and presented preliminary results. Ben Johnson (BJ), health economist, then provided an overview of the economic analyses conducted for this question.</p> <p>The committee discussed the evidence presented and answered the questions posed by the analysts. No recommendations were made as the analysis was deliberately incomplete. This topic will be revisited in March when the full analysis, incorporating the information obtained at this meeting, will be available.</p>			
<p>4. Review question - Management of stable COPD (clinical):</p> <p><i>In people with stable COPD, what is the clinical and cost effectiveness of a long-acting muscarinic antagonist (LAMA) plus a LABA compared with:</i></p> <ul style="list-style-type: none"> <i>- a LAMA alone</i> <i>- a LABA alone</i> <i>- a LABA plus an inhaled corticosteroid (ICS)</i> 			
<p>The inhaled therapy combination question is being carried out as a collaboration with the Cochrane airways group and will be presented in full at a later date. In the meantime, MH presented the Cochrane review protocol for the committee’s consideration and asked for feedback on a number of issues that needed clarifying. BJ then provided an overview of the published economic analyses conducted for this question.</p>			

Committee minutes – COPD meeting 6

The committee discussed the economic evidence presented and answered the questions posed by the both analysts. No recommendations were made and this question will be discussed again in March when the results of the analysis carried out by the Cochrane group and the original economic model will be available.

5. Economics

BJ gave an update on the progress of the health economic model since the last meeting and sought the committee’s clinical expertise to inform the model design.

6. AOB and summary of meeting

The chair thanked the committee for attending and confirmed the date of the next meeting (see below).

The committee asked the NICE team to consider rescheduling the last meeting in April due to Easter holidays.

Next meeting:

Tuesday 16th January, Bollin, Manchester NICE Offices